These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31914839)

  • 1. 5 years of clinical DC-CIK/NK cells immunotherapy for acute myeloid leukemia - a summary.
    Zhang X; Yang J; Zhang G; Song L; Su Y; Shi Y; Zhang M; He J; Song D; Lv F; Wu P; Wang H; Wang T; Zhang Y; Liu H; Lu P
    Immunotherapy; 2020 Jan; 12(1):63-74. PubMed ID: 31914839
    [No Abstract]   [Full Text] [Related]  

  • 2. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
    J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the Clinical Efficacy of Dendritic Cell -cytokine Induced Killer Cell-based Adoptive Immunotherapy for Colorectal Cancer.
    Xu H; Qin W; Feng H; Song D; Yang X; Zhang J
    Immunol Invest; 2021 Aug; 50(6):622-633. PubMed ID: 32718264
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of dendritic cell-activated and cytokine-induced killer cell therapy on 22 children with acute myeloid leukemia after chemotherapy.
    Bai Y; Zheng JE; Wang N; Cai HH; Zhai LN; Wu YH; Wang F; Jin RM; Zhou DF
    J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):689-693. PubMed ID: 26489623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
    Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients.
    Zhang L; Mu Y; Zhang A; Xie J; Chen S; Xu F; Wang W; Zhang Y; Ren S; Zhou C
    Oncotarget; 2017 Jul; 8(28):45164-45177. PubMed ID: 28404886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effect and safety of dendritic cell-cytokine-induced killer cell immunotherapy for pancreatic cancer: a systematic review and meta-analysis.
    Liu YL; Yang LX; Zhang F; Tang BS; Zhao LT; Zhu JR; Jin QY; Wang RX; Li YM
    Cytotherapy; 2019 Oct; 21(10):1064-1080. PubMed ID: 31462394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study.
    Lin T; Song C; Chuo DY; Zhang H; Zhao J
    Tumour Biol; 2016 Apr; 37(4):4367-72. PubMed ID: 26499782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment.
    Xie Y; Huang L; Chen L; Lin X; Chen L; Zheng Q
    World J Surg Oncol; 2017 Nov; 15(1):209. PubMed ID: 29179719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response.
    Li C; Zhu D; Zhao Y; Guo Q; Sun W; Li L; Gao D; Zhao P
    Immunol Invest; 2020 Jul; 49(5):522-534. PubMed ID: 31793363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences.
    Ren J; Di L; Song G; Yu J; Jia J; Zhu Y; Yan Y; Jiang H; Liang X; Che L; Zhang J; Wan F; Wang X; Zhou X; Lyerly HK
    Clin Transl Oncol; 2013 Oct; 15(10):780-8. PubMed ID: 23359185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The cytotoxicity of CIK/NK cells stimulated by K562-DC fusion vaccines in NOD/SCID mice model for human erythroleukemia].
    Li Y; Huang SL; Zhang XC; Fang JP; Wu YF; Wei J; Huang WG; Zhou DH; Huang K; Lin YC
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):39-43. PubMed ID: 18512314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: A meta-analysis.
    He G; Zheng C; Huo H; Zhang H; Zhu Z; Li J; Zhang H
    Int Immunopharmacol; 2016 Nov; 40():436-442. PubMed ID: 27716591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis.
    Wang ZX; Cao JX; Liu ZP; Cui YX; Li CY; Li D; Zhang XY; Liu JL; Li JL
    World J Gastroenterol; 2014 Jan; 20(4):1095-106. PubMed ID: 24574784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of dendritic cell-cytokine induced killer cells combined with concurrent chemoradiotherapy on locally advanced non-small cell lung cancer.
    Tian L; Wang W; Yu B; Zhang G
    J BUON; 2020; 25(5):2364-2370. PubMed ID: 33277857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma.
    Zhao X; Zhang Z; Li H; Huang J; Yang S; Xie T; Huang L; Yue D; Xu L; Wang L; Zhang W; Zhang Y
    Cancer Lett; 2015 Jul; 362(2):192-8. PubMed ID: 25843292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
    Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.
    Jiang N; Qiao G; Wang X; Morse MA; Gwin WR; Zhou L; Song Y; Zhao Y; Chen F; Zhou X; Huang L; Hobeika A; Yi X; Xia X; Guan Y; Song J; Ren J; Lyerly HK
    Clin Cancer Res; 2017 Sep; 23(17):5066-5073. PubMed ID: 28611200
    [No Abstract]   [Full Text] [Related]  

  • 20. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients.
    Yang L; Ren B; Li H; Yu J; Cao S; Hao X; Ren X
    Cancer Immunol Immunother; 2013 Jan; 62(1):65-73. PubMed ID: 22744010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.